Trial Profile

A randomized Phase 2 ASPEN-Breast clinical trial will evaluate evorpacept with HERCEPTIN (trastuzumab) and single-agent chemotherapy in patients with HER2-positive metastatic breast cancer after prior treatment with ENHERTU(fam-trastuzumab deruxtecan-nxki).

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 May 2025 According to an ALX Oncology media release, interim results from this trial are anticipated in 2H 2026.
17 Mar 2025 New trial record
06 Mar 2025 According to an ALX Oncology media release, patient dosing anticipated to initiate for ASPEN-BREAST Phase 2 clinical trial in mid-year 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com